Badanie w przypadku opornej na leczenie cukrzycy typu 2 (CAPTAIN-T2D) (CAPTAIN-T2D)
Badanie fazy 2 preparatu Clofutriben i placebo w leczeniu opornej cukrzycy typu 2 (CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.
The trial consists of two parts.
Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.
During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Arizona
-
Chandler, Arizona, Stany Zjednoczone, 85225
- Rekrutacyjny
- Arizona Clinical Trials - Pecos
-
Kontakt:
- Kamila Manager
- Numer telefonu: 480-470-4000
- E-mail: kojeda@azclinicaltrials.com
-
Tucson, Arizona, Stany Zjednoczone, 85711
- Rekrutacyjny
- Arizona Clinical Trials - Broadway
-
Kontakt:
- Leanne Manager
- Numer telefonu: 480-470-4000
- E-mail: lbuchenholz@azclinicaltrials.com
-
-
California
-
Fountain Valley, California, Stany Zjednoczone, 92708
- Rekrutacyjny
- Ark Clinical Research - Fountain Valley
-
Kontakt:
- Lizeth Manager
- Numer telefonu: 323-588-1990
- E-mail: lsuncin@velocityclinical.com
-
Huntington Park, California, Stany Zjednoczone, 90255
- Rekrutacyjny
- Velocity Clinical Research, Huntington Park
-
Kontakt:
- Tim Manager
- Numer telefonu: 5135799911
- E-mail: tpeterson@velocityclinical.com
-
La Mesa, California, Stany Zjednoczone, 91942
- Rekrutacyjny
- Velocity Clinical Research - Gardena
-
Kontakt:
- Tim Manager
- Numer telefonu: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Long Beach, California, Stany Zjednoczone, 90815
- Rekrutacyjny
- Ark Clinical Research - Long Beach
-
Kontakt:
- Mike Manager
- Numer telefonu: 562-997-1000
- E-mail: mdelgado@arkclinicalresearch.com
-
Los Angeles, California, Stany Zjednoczone, 90057
- Rekrutacyjny
- Velocity Clinical Research, Los Angeles
-
Kontakt:
- Tim Manager
- Numer telefonu: 5135799911
- E-mail: tpeterson@velocityclinical.com
-
Los Angeles, California, Stany Zjednoczone, 90015
- Rekrutacyjny
- Los Angeles Institute for Metabolic Research
-
Kontakt:
- Lourdes Manager
- Numer telefonu: (213) 373-8380
- E-mail: lgaribay@metabolic.la
-
Northridge, California, Stany Zjednoczone, 98433
- Rekrutacyjny
- Amicis Research Center- Nordhoff
-
Kontakt:
- Veronica Clinical Research Manager
- Numer telefonu: (818) 929-7774
- E-mail: veronica.macias@amicisresearch.com
-
San Diego, California, Stany Zjednoczone, 92120
- Rekrutacyjny
- Alliance Clinical San Diego
-
Kontakt:
- Sandra Manager
- Numer telefonu: (858) 299-0009
- E-mail: SMisic@allianceclinicalnetwork.com
-
-
Florida
-
Edgewater, Florida, Stany Zjednoczone, 32132
- Rekrutacyjny
- Velocity Clinical Research, New Smyrna Beach
-
Kontakt:
- Tim Manager
- Numer telefonu: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33312
- Rekrutacyjny
- The Center for Diabetes and Endocrine Care
-
Kontakt:
- Marie Study Coordinator
- Numer telefonu: ext 236 954-963-7191
- E-mail: mmartin@diabetes-endocare.com
-
Miami, Florida, Stany Zjednoczone, 33173
- Rekrutacyjny
- Admed Research LLC
-
Kontakt:
- Indiana Manager
- Numer telefonu: 786-687-2882
- E-mail: igonzalez@admedresearch.com
-
New Port Richey, Florida, Stany Zjednoczone, 34652
- Rekrutacyjny
- Suncoast Clinical Research, Inc
-
Kontakt:
- Cathy Manager
- Numer telefonu: 727-849-4131
- E-mail: cbarnes@suncoastclinicalresearch.com
-
Port Charlotte, Florida, Stany Zjednoczone, 33952
- Rekrutacyjny
- Innovative Research Institute
-
Kontakt:
- Lauren Manager
- Numer telefonu: (+1) 2832276233
- E-mail: l.ellis@medpace.com
-
Port Orange, Florida, Stany Zjednoczone, 32127
- Rekrutacyjny
- Progressive Medical Research
-
Kontakt:
- Nora Clinical Research Manager
- Numer telefonu: 3457 386-304-7070
- E-mail: norab@progressivemedicalresearch.com
-
Winter Park, Florida, Stany Zjednoczone, 32789
- Rekrutacyjny
- Conquest Research
-
Kontakt:
- Malisa Manager
- Numer telefonu: 407-916-0060
- E-mail: malisa.agard@conquestresearch.com
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30303
- Rekrutacyjny
- Emory University School of Medicine
-
Kontakt:
- Rohit Manager
- Numer telefonu: 404-778-1695
- E-mail: rohit.parab@emory.edu
-
Columbus, Georgia, Stany Zjednoczone, 31904
- Rekrutacyjny
- IACT Health-Brookstone Centre Pkwy
-
Kontakt:
- kristina Manager
- Numer telefonu: 706.321.0495
- E-mail: kristina.erb@centricityresearch.com
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83709
- Rekrutacyjny
- Paradigm Clinical Research - Boise, ID
-
Kontakt:
- Janaie Manager
- Numer telefonu: 208-801-7440
- E-mail: jbounsana@paradigm-research.com
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60607
- Rekrutacyjny
- Chicago Clinical Research Institute
-
Kontakt:
- Manognya Clinical Research Manager
- Numer telefonu: 303 3127913241
- E-mail: manognya@ccrii.us
-
-
Iowa
-
West Des Moines, Iowa, Stany Zjednoczone, 50226
- Rekrutacyjny
- Iowa Diabetes and Endocrinology Research Center
-
Kontakt:
- Crystal Manager
- Numer telefonu: 515-207-7486
- E-mail: choffman@iderc.com
-
-
Kansas
-
Wichita, Kansas, Stany Zjednoczone, 67226
- Rekrutacyjny
- Alliance for Multispecialty Research - Wichita East
-
Kontakt:
- Terry Manager
- Numer telefonu: 316-689-6635
- E-mail: terry.klein@amr-clinical.com
-
-
Kentucky
-
Edgewood, Kentucky, Stany Zjednoczone, 41017
- Rekrutacyjny
- St. Elizabeth Healthcare
-
Kontakt:
- Amber Manager
- Numer telefonu: 859-655-1567
- E-mail: amber.avery@stelizabeth.com
-
-
Louisiana
-
Lafayette, Louisiana, Stany Zjednoczone, 70508
- Rekrutacyjny
- Velocity Clinical Research, Lafayette
-
Kontakt:
- Tim Manager
- Numer telefonu: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Metairie, Louisiana, Stany Zjednoczone, 70006
- Rekrutacyjny
- NOLA Care Clinical Research
-
Kontakt:
- Rosina Manager
- Numer telefonu: 504-427-6324
- E-mail: rosinaducote@gmail.com
-
New Orleans, Louisiana, Stany Zjednoczone, 70112
- Rekrutacyjny
- Tulane University School of Medicine
-
Kontakt:
- Neha Manager
- Numer telefonu: 5049889803
- E-mail: nupadhyay@tulane.edu
-
-
Maryland
-
Rockville, Maryland, Stany Zjednoczone, 20854
- Rekrutacyjny
- Velocity Clinical Research, Rockville
-
Kontakt:
- Tim Manager
- Numer telefonu: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
-
Massachusetts
-
Springfield, Massachusetts, Stany Zjednoczone, 011030
- Rekrutacyjny
- Elixia SISU BHR - Springfield
-
Kontakt:
- Darlene Manager
- Numer telefonu: 5617970336
- E-mail: darlene.djaba@empathxresearch.com
-
-
Michigan
-
Troy, Michigan, Stany Zjednoczone, 48085
- Rekrutacyjny
- Oakland Medical Research Center
-
Kontakt:
- Juliejo (Julie) Clinical Research Manager
- Numer telefonu: 248-687-7412
- E-mail: juliejolafave@msn.com
-
-
Nebraska
-
Lincoln, Nebraska, Stany Zjednoczone, 68510
- Rekrutacyjny
- Velocity Clinical Research, Lincoln
-
Kontakt:
- Tim Manager
- Numer telefonu: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Omaha, Nebraska, Stany Zjednoczone, 68134
- Rekrutacyjny
- Velocity Clinical Research, Omaha
-
Kontakt:
- Tim Manager
- Numer telefonu: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89148
- Rekrutacyjny
- Palm Research Center, Inc.
-
Kontakt:
- Raffaela Manager
- Numer telefonu: 702-736-5161
- E-mail: raffaela@palmresearchcenter.com
-
Las Vegas, Nevada, Stany Zjednoczone, 89108
- Rekrutacyjny
- Alliance Clinical - Las Vegas
-
Kontakt:
- Stephanie Manager
- Numer telefonu: (702) 680-1500
- E-mail: sruvalcaba@allianceclinicalnetwork.com
-
-
New York
-
Albany, New York, Stany Zjednoczone, 12203
- Rekrutacyjny
- Albany Medical College
-
Kontakt:
- Mohammed Manager
- Numer telefonu: 518-264-4462
- E-mail: ismailmoh@amc.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27514
- Rekrutacyjny
- University of North Carolina at Chapel Hill
-
Kontakt:
- Jessica Manager
- Numer telefonu: 984-974-3004
- E-mail: jessica_caffey@med.unc.edu
-
Greenville, North Carolina, Stany Zjednoczone, 27834
- Rekrutacyjny
- Physicians East
-
Kontakt:
- Kristen Manager
- Numer telefonu: 252-413-6392
- E-mail: ktaylor@physicianseast.com
-
Morehead City, North Carolina, Stany Zjednoczone, 28557
- Rekrutacyjny
- Lucas Research Inc
-
Kontakt:
- Christina Manager
- Numer telefonu: 252-222-5700
- E-mail: christina.tornes@centricityresearch.com
-
Wilmington, North Carolina, Stany Zjednoczone, 28401
- Rekrutacyjny
- PMG Research of Wilmington, LLC
-
Kontakt:
- Kevin Manager
- Numer telefonu: 910.815.6108
- E-mail: cannon1099@me.com
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45219
- Rekrutacyjny
- Velocity Clinical Research, Cincinnati, Mt. Auburn
-
Kontakt:
- Tim Manager
- Numer telefonu: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Cincinnati, Ohio, Stany Zjednoczone, 45242
- Rekrutacyjny
- Velocity Clinical Research - Cincinnati, Blue Ash
-
Kontakt:
- Tim Manager
- Numer telefonu: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Columbus, Ohio, Stany Zjednoczone, 43201
- Rekrutacyjny
- Endocrinology Associates, Inc
-
Kontakt:
- Edward Clinical Research Manager
- Numer telefonu: 614-453-9999
- E-mail: ek@endocrinology-associates.com
-
Columbus, Ohio, Stany Zjednoczone, 43215
- Rekrutacyjny
- Remington Davis, Inc
-
Kontakt:
- Tsunami Clinical Research Manager
- Numer telefonu: 614-487-2560
- E-mail: Tbrisco@remdavis.com
-
-
Oregon
-
Eugene, Oregon, Stany Zjednoczone, 97404
- Rekrutacyjny
- Willamette Valley Clinical Studies
-
Kontakt:
- Patricia Manager
- Numer telefonu: 541-461-0132
- E-mail: drpatb@aol.com
-
-
Pennsylvania
-
West Chester, Pennsylvania, Stany Zjednoczone, 19380
- Rekrutacyjny
- Suburban Research Associates
-
Kontakt:
- Tom Manager
- Numer telefonu: 610-891-9024
- E-mail: tfrancis@suburbanresearch.com
-
-
South Carolina
-
Anderson, South Carolina, Stany Zjednoczone, 29621
- Rekrutacyjny
- Velocity Clinical Research, Anderson
-
Kontakt:
- Tim Manager
- Numer telefonu: (864) 965-0190
- E-mail: tpeterson@velocityclinical.com
-
Mt. Pleasant, South Carolina, Stany Zjednoczone, 29464
- Rekrutacyjny
- Accellacare Charleston
-
Kontakt:
- Dhruva Manager
- Numer telefonu: (843) 849-1880
- E-mail: dhruva.patel@accellacare.com
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78759
- Rekrutacyjny
- Velocity Clinical Research, Austin
-
Kontakt:
- Tim Manager
- Numer telefonu: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Dallas, Texas, Stany Zjednoczone, 75230
- Rekrutacyjny
- Velocity Clinical Research - Dallas
-
Kontakt:
- Tim Manager
- Numer telefonu: (972) 566-8631
- E-mail: tpeterson@velocityclinical.com
-
Houston, Texas, Stany Zjednoczone, 77040
- Rekrutacyjny
- Juno Research, LLC
-
Kontakt:
- Lian manager
- Numer telefonu: 713-779-5494
- E-mail: lian_ramos@junoresearch.us
-
Lampasas, Texas, Stany Zjednoczone, 76550
- Rekrutacyjny
- Radiance Clinical Research
-
Kontakt:
- Lauren Clinical Research Manager
- Numer telefonu: 512-556-4130
- E-mail: lgarner@radianceclinical.com
-
Lewisville, Texas, Stany Zjednoczone, 75057
- Rekrutacyjny
- Alliance Clinical - Lewisville (Epic Clinical Research)
-
Kontakt:
- Jessica Manager
- Numer telefonu: (469) 361-8007
- E-mail: jpowell@allianceclinicalnetwork.com
-
Mission, Texas, Stany Zjednoczone, 78572
- Rekrutacyjny
- Texas Valley Clinical Research - Mission, TX
-
Kontakt:
- Omar Manager
- Numer telefonu: 9568887400
- E-mail: gonzalez.md@tvcrmission.com
-
Round Rock, Texas, Stany Zjednoczone, 78681
- Rekrutacyjny
- Texas Diabetes & Endocrinology, P.A. - Round Rock
-
Kontakt:
- Olivia Clinical Research Manager
- Numer telefonu: 512-334-3505
- E-mail: knutty@tderesearch.com
-
San Antonio, Texas, Stany Zjednoczone, 78229
- Rekrutacyjny
- Diabetes & Glandular Disease Clinic, P.A.
-
Kontakt:
- Myriam Manager
- Numer telefonu: 1532 210-614-8612
- E-mail: myriam.turner@dgdclinic.com
-
San Antonio, Texas, Stany Zjednoczone, 78251
- Rekrutacyjny
- Texas Valley Clinical Research - San Antonio TX
-
Kontakt:
- Diana Manager
- Numer telefonu: 2105431990
- E-mail: diana@tvcrtrials.com
-
Seabrook, Texas, Stany Zjednoczone, 77586
- Rekrutacyjny
- Elevate Clinical Research
-
Kontakt:
- Olga Clinical Research Manager
- Numer telefonu: 832-271-1598
- E-mail: olga.konshina@elevateclinical.com
-
Weslaco, Texas, Stany Zjednoczone, 78596
- Rekrutacyjny
- Texas Valley Clinical Research, LLC
-
Kontakt:
- Czarina Manager
- Numer telefonu: 956-431-8090
- E-mail: czarina@tvcrtrials.com
-
-
Utah
-
West Jordan, Utah, Stany Zjednoczone, 84088
- Rekrutacyjny
- Velocity Clinical Research, Salt Lake City
-
Kontakt:
- Tim Clinical Research Manager
- Numer telefonu: 5135799911
- E-mail: tpeterson@velocityclinical.com
-
-
Virginia
-
Suffolk, Virginia, Stany Zjednoczone, 23435
- Rekrutacyjny
- Velocity Clinical Research, Suffolk
-
Kontakt:
- Tim Manager
- Numer telefonu: (757) 996-4200
- E-mail: tpeterson@velocityclinical.com
-
Vienna, Virginia, Stany Zjednoczone, 22182
- Rekrutacyjny
- Conquest Research
-
Kontakt:
- Henry Manager
- Numer telefonu: 703-372-3268
- E-mail: Henry.Tran@conquestresearch.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
From Screening 1
-
Age at least 18 years.
-
HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).
-
Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).
-
Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.
-
Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.
-
At least one of the following
- ≥3 stable and adequate ADMs;
- diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
- hypertension requiring ≥2 adequately dosed AHMs;
- adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
- adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
- evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
- or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.
-
At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.
At Screening 2
- HbA1c ≥7.5% at Screening 2. At Day 1
- No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.
Exclusion Criteria:
-
New-onset diabetes (onset <1 year in the past).
-
Unwillingness to maintain with current glucose-lowering regimen during the trial.
-
Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.
-
Unwillingness to comply with CGM or other trial procedures.
-
Investigator considers the patient will otherwise be unwilling or unable to complete the trial.
-
Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.
-
Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).
-
Any of the following in medical history:
- Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
- A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
- Hypersensitivity or severe reaction to dexamethasone;
- Pheochromocytoma, or suspicion thereof;
- Anorexia, or other eating disorder;
- Glucocorticoid resistance;
- Multiple sclerosis;
- Significant hepatic impairment (e.g., Child-Pugh Class B or C);
- Idiopathic thrombocytopenic purpura;
- Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
- Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
- Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
- Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
- Any of the following in medication history:
- Any of the excluded medications listed in Section 6.9;
- Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
- Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
- Pregnancy (including a positive urine test) or current breast feeding.
From Screening 2
• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:
- wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
- a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
- supraclavicular/dorsocervical fat accumulation;
- irounding of the face (especially compared with prior photos);
- skin changes (violaceous striae, skin thinning, or excessive bruising);
- proximal muscle weakness on exam; or
- history of deep vein thrombosis/pulmonary embolism.
- Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
- Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
- Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
- Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
- Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
- Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
- Known hypersensitivity to clofutriben or to any of the product
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Dose 1
clofutriben .2 mg oral tablet daily |
HSD-1 inhibitor
Inne nazwy:
|
|
Eksperymentalny: Dose 2
clofutriben 2mg oral tablet daily |
HSD-1 inhibitor
Inne nazwy:
|
|
Eksperymentalny: Dose 3
clofutriben 6mg oral tablet daily |
HSD-1 inhibitor
Inne nazwy:
|
|
Eksperymentalny: Dose 4
clofutriben 12 mg oral tablet daily |
HSD-1 inhibitor
Inne nazwy:
|
|
Komparator placebo: placebo
placebo control oral tablet daily |
Placebo |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Ramy czasowe: 8-10 hours after the dexamethasone 1 mg dose.
|
To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose. |
8-10 hours after the dexamethasone 1 mg dose.
|
|
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Ramy czasowe: 24 weeks.
|
To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks.
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Ramy czasowe: 24 weeks
|
To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To evaluate the safety of clofutriben in participants with T2D and EC.
Ramy czasowe: From enrollment until end of trial 9 month
|
Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose |
From enrollment until end of trial 9 month
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu hormonalnego
- Nowotwory
- Choroby metaboliczne
- Zaburzenia metabolizmu glukozy
- Cukrzyca
- Zespoły paranowotworowe
- Choroby nadnerczy
- Nadczynność kory nadnerczy
- Paranowotworowe zespoły endokrynologiczne
- Choroby żywieniowe i metaboliczne
- Cukrzyca typu 2
- Zespół Cushinga
- Zespół ACTH, ektopowy
- ASP3662
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- SPI-62-CL-2006
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .